Details

Autor(en) / Beteiligte

• López-Neyra, Alejandro
• Suárez, Lucrecia
• Muñoz, Marta
• de Blas, Ana
• Ruiz de Valbuena, Marta
• Garriga, María
• Calvo, Joaquim
• Ribes, Carmen
• Girón Moreno, Rosa
• Máiz, Luis
• González, David
• Bousoño, Carlos
• Manzanares, Javier
• Pastor, Óscar
• Martínez-Botas, Javier
• del Campo, Rosa
• Cantón, Rafael
• Roy, Garbiñe
• Menacho, Miriam
• Arroyo, David
• Zamora, Javier
• Soriano, Joan B
• Lamas, Adelaida

Titel

Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial

Ist Teil von

• Prostaglandins, leukotrienes and essential fatty acids, 2020-11, Vol.162, p.102186-102186, Article 102186

Ort / Verlag

Scotland: Elsevier Ltd

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Inflammation has a key role in cystic fibrosis pathophysiology•Benefits of docosahexaenoic acid (DHA) in cystic fibrosis inflammation are controversial•Long-term supplementation with DHA in CF did not improve inflammatory biomarkers•Long-term supplementation with DHA in CF did not improve clinical outcomes Cystic fibrosis (CF) patients have an alteration in fatty acid (FA) metabolism, associated with increased omega-6 and low omega-3 FA. Previous studies on supplementation with omega-3 FA in CF had contradictory results, and to date there is no evidence to recommend routine use of omega-3 supplements in CF patients. We hypothesized that long-term supplementation with docosahexaenoic acid (DHA) will have beneficial effects in these patients, by reducing pulmonary, systemic and intestinal inflammation. This was a randomized, double-blind, parallel, placebo-controlled trial. CF patients (age >2 months) were randomized to receive a seaweed DHA oil solution (50 mg/Kg/day) or matching placebo for 48 weeks. Primary outcomes were pulmonary (interleukin [IL]-8), systemic (IL-8) and intestinal (calprotectin) inflammatory biomarkers. Secondary outcomes included other pulmonary (IL-1β, IL-6, neutrophil elastase, lactate and calprotectin) and systemic (serum-IL-1β, IL-6) inflammatory biomarkers, as well as clinical outcomes (FEV1, pulmonary exacerbations, antibiotic use, nutritional status and quality of life). Ninety six CF patients, 44 female, age 14.6±11.9 years (48 DHA and 48 placebo) were included. At trial completion, there were no differences in all primary outcomes [serum-IL-8 (p=0.909), respiratory-IL-8 (p=0.384) or fecal calprotectin (p=0.948)], all secondary inflammatory biomarkers, or in any of the clinical outcomes evaluated. There were few adverse events, with similar incidence in both study groups. In this study, long-term DHA supplementation in CF patients was safe, but did not offer any benefit on inflammatory biomarkers, or in clinical outcomes compared with placebo. (NCT01783613)